@article{39091ec8a37f482cad4806fa38cbe855,
title = "RT-PCR screening tests for SARS-CoV-2 with saliva samples in asymptomatic people: Strategy to maintain social and economic activities while reducing the risk of spreading the virus",
abstract = "The year 2020 will be remembered for the coronavirus disease 2019 (COVID-19) pandemic, which continues to affect the whole world. Early and accurate identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is fundamental to combat the disease. Among the current diagnostic tests, real-time reverse transcriptase–polymerase chain reaction (RT-qPCR) is the most reliable and frequently used method. Herein, we discuss the interpretation of RT-qPCR results relative to viral infectivity. Although nasopharyngeal swab samples are often used for RT-qPCR testing, they require collection by trained medical staff. Saliva samples are emerging as an inexpensive and efficient alternative for large-scale screening. Pooled-sample testing of saliva has been applied for mass screening of SARS-CoV-2 infection. Current policies recommend isolating people with borderline cycle threshold (Ct) values (35<Ct <40), despite these Ct values indicating minimal infection risk. We propose the new concept of a “social cut-off” Ct value and risk stratification based on the correlation of Ct with infectivity. We also describe the experience of RT-qPCR screening of saliva samples at our institution. It is important to implement a scientific approach to minimize viral transmission while allowing economic and social activities to continue.",
keywords = "COVID-19, Mass screening, Real-time polymerase chain reaction, SARS-CoV-2, Saliva",
author = "Junna Oba and Hiroaki Taniguchi and Masae Sato and Reika Takamatsu and Satoru Morikawa and Taneaki Nakagawa and Hiromasa Takaishi and Hideyuki Saya and Koichi Matsuo and Hiroshi Nishihara",
note = "Funding Information: The authors would like to thank Ms. Kaori Mochida, Ms. Emmy Yanagida, Mr. Hiroshi Yamada, Mr. Hiroumi Kurogi, and Ms. Matsumi Hirose for their technical as-sistance; Dr. Scott E. Woodman (Houston, TX, USA) for proofreading our manuscript; and Dr. A. Gordon Robert-son (Courtenay, BC, Canada) for his helpful advice on data visualization and valuable manuscript discussions. The Keio Donner Project was launched in early 2020 to promote research to clarify the mechanism of COVID-19 disease, increase diagnostic test capacity, and develop effective therapeutic options. The name “Donner” is de-rived from the late Professor S. Kitasato, the founder of the Keio University School of Medicine. Special thanks to Masatoshi Wakui, MD, PhD; Yoshifumi Uwamino, MD, PhD; Toshinobu Kurafuji; Masayo Noguchi; Akemi Ohno; Hiromitsu Yokota, PhD; Haruhito Kikuchi; MD; PhD, Naoki Hasegawa, MD, PhD; Mitsuru Murata, MD, PhD; Yuko Kitagawa, MD, PhD; and Masayuki Am-agai, MD, PhD for their contribution to the Keio Donner Project. This work was partially supported by the Keio University Global Research Institute (KGRI) Research Projects for New Coronavirus Crisis: Implementation of a Keio Model to Optimize SARS-CoV-2 PCR Tests through Systems Approach (PI: Koichi Matsuo); the Japan Agen-cy for Medical Research and Development (AMED) (PI: Hiroshi Nishihara, Grant Number 20he1422004j0001); and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) for utilization of the university{\textquoteright}s PCR equipment. The funding agencies had no role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Funding Information: The authors would like to thank Ms. Kaori Mochida, Ms. Emmy Yanagida, Mr. Hiroshi Yamada, Mr. Hiroumi Kurogi, and Ms. Matsumi Hirose for their technical assistance; Dr. Scott E. Woodman (Houston, TX, USA) for proofreading our manuscript; and Dr. A. Gordon Robertson (Courtenay, BC, Canada) for his helpful advice on data visualization and valuable manuscript discussions. The Keio Donner Project was launched in early 2020 to promote research to clarify the mechanism of COVID-19 disease, increase diagnostic test capacity, and develop effective therapeutic options. The name “Donner” is derived from the late Professor S. Kitasato, the founder of the Keio University School of Medicine. Special thanks to Masatoshi Wakui, MD, PhD; Yoshifumi Uwamino, MD, PhD; Toshinobu Kurafuji; Masayo Noguchi; Akemi Ohno; Hiromitsu Yokota, PhD; Haruhito Kikuchi; MD; PhD, Naoki Hasegawa, MD, PhD; Mitsuru Murata, MD, PhD; Yuko Kitagawa, MD, PhD; and Masayuki Am-agai, MD, PhD for their contribution to the Keio Donner Project. This work was partially supported by the Keio University Global Research Institute (KGRI) Research Projects for New Coronavirus Crisis: Implementation of a Keio Model to Optimize SARS-CoV-2 PCR Tests through Systems Approach (PI: Koichi Matsuo); the Japan Agency for Medical Research and Development (AMED) (PI: Hiroshi Nishihara, Grant Number 20he1422004j0001); and the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) for utilization of the university{\textquoteright}s PCR equipment. The funding agencies had no role in the study design; in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2021, Keio University School of Medicine. All rights reserved.",
year = "2021",
doi = "10.2302/kjm.2021-0003-OA",
language = "English",
volume = "70",
pages = "35--43",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "2",
}